The DIAMOND for the Treatment of Type 2 Diabetes: Can Blood Triglycerides level be the predictor for therapy efficiency?

Metacure Ltd.0 个研究点目标入组 45 人开始时间: 2014年5月20日最近更新: 2016年5月30日

适应症

试验速览

暂无简介。

•Male and female subjects 18 through 70 years of age
•Body mass index > 30 and < 45 (kg/m2)
•Type 2 diabetes duration of at least 6 months
•Type 2 diabetic subjects treated with oral anti-diabetic agents [Sulfonylurea, Metformin, thiazolinedione (TZD) or DPP-4 inhibitors]
•Stable anti-diabetic medications for at least 3 months prior to enrollment, six months for thiazolinedione (TZD)
•The subject has been under routine diabetes care of the investigator or another single physician that can supply a medical record for at least 6 months prior to enrollment
•HbA1c ?7.3% and = 9.5 % on Visit 1
•Stable HbA1c, defined as no significant change (variation = 0.5%) between a historical value recorded in the subject’s medical record within 3 months prior to enrollment and the HbA1c gathered on Visit 1.
•Fasting blood glucose >120 and < 350 mg/dl on Visit 1.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 45
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Insulin therapy in last 3 months
•Taking GLP-1 agonists or in the last 3 months before the enrollment
•Currently taking fibrates, nicotinamide and omega 3 fatty acids as antilipidemic treatment

发起方

Metacure Ltd.